Evidence map›Paper›PMID 25839150›Full record

ArticleNeuroscience2015

Electrophysiological characterization of activation state-dependent Ca(v)2 channel antagonist TROX-1 in spinal nerve injured rats.

R Patel, K Rutten, M Valdor, K Schiene, S Wigge, S Schunk, N Damann, T Christoph, A H Dickenson

Open access · hybridAbstract read
In one paragraph

Article in Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Voltage-dependent CaPflugers Archiv : European journal of physiology · 2022
    Review
  5. Heat But Not Mechanical Hypersensitivity Depends on Voltage-Gated CaThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  6. Review
  7. Translational issues in precision medicine in neuropathic pain.Canadian journal of pain = Revue canadienne de la douleur · 2020
    Review
  8. Article
  9. Article
  10. Review
  11. Breaking barriers to novel analgesic drug development.Nature reviews. Drug discovery · 2017
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

R PatelUniversity College London, Gower Street, Department of Neuroscience, Physiology and Pharmacology, London WC1E 6BT, UK. Electronic address: ryan.patel.10@ucl.ac.uk.
K RuttenGrünenthal GmbH, Global Preclinical Research, 52078 Aachen, Germany.
M ValdorGrünenthal GmbH, Global Preclinical Research, 52078 Aachen, Germany.
K SchieneGrünenthal GmbH, Global Preclinical Research, 52078 Aachen, Germany.
S WiggeGrünenthal GmbH, Global Preclinical Research, 52078 Aachen, Germany.
S SchunkGrünenthal GmbH, Global Preclinical Research, 52078 Aachen, Germany.
N DamannGrünenthal GmbH, Global Preclinical Research, 52078 Aachen, Germany.
T ChristophGrünenthal GmbH, Global Preclinical Research, 52078 Aachen, Germany.
A H DickensonUniversity College London, Gower Street, Department of Neuroscience, Physiology and Pharmacology, London WC1E 6BT, UK.
Grünenthal Group (Germany) · DEUniversity College London · GB

Funding

Biotechnology and Biological Sciences Research Council BB/H016597/1
6 · The paper itself

Abstract

Prialt, a synthetic version of Ca(v)2.2 antagonist ω-conotoxin MVIIA derived from Conus magus, is the first clinically approved voltage-gated calcium channel blocker for refractory chronic pain. However, due to the narrow therapeutic window and considerable side effects associated with systemic dosing, Prialt is only administered intrathecally. N-triazole oxindole (TROX-1) is a novel use-dependent and activation state-selective small-molecule inhibitor of Ca(v)2.1, 2.2 and 2.3 calcium channels designed to overcome the limitations of Prialt. We have examined the neurophysiological and behavioral effects of blocking calcium channels with TROX-1. In vitro, TROX-1, in contrast to state-independent antagonist Prialt, preferentially inhibits Ca(v)2.2 currents in rat dorsal root ganglia (DRG) neurons under depolarized conditions. In vivo electrophysiology was performed to record from deep dorsal horn lamina V/VI wide dynamic range neurons in non-sentient spinal nerve-ligated (SNL) and sham-operated rats. In SNL rats, spinal neurons exhibited reduced responses to innocuous and noxious punctate mechanical stimulation of the receptive field following subcutaneous administration of TROX-1, an effect that was absent in sham-operated animals. No effect was observed on neuronal responses evoked by dynamic brushing, heat or cold stimulation in SNL or sham rats. The wind-up response of spinal neurons following repeated electrical stimulation of the receptive field was also unaffected. Spinally applied TROX-1 dose dependently inhibited mechanically evoked neuronal responses in SNL but not sham-operated rats, consistent with behavioral observations. This study confirms the pathological state-dependent actions of TROX-1 through a likely spinal mechanism and reveals a modality selective change in calcium channel function following nerve injury.

Indexed as

AcetoneAction PotentialsAnimalsCalcium Channel BlockersDisease Models, AnimalDose-Response Relationship, DrugElectric StimulationGanglia, SpinalHyperalgesiaIndolesMaleomega-ConotoxinsPain MeasurementPain ThresholdPatch-Clamp TechniquesPeripheral Nerve Injuries5-(3-chloro-4-fluorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1-(1H-1,2,4-triazol-3-yl)-1,3-dihydro-2H-indol-2-oneAcetoneCalcium Channel BlockersIndolesomega-ConotoxinsTriazolesziconotideCa(v)2.2dorsal horndorsal root gangliaelectrophysiologyN-type calcium channelspinal nerve ligation

Identifiers

PMID25839150
PMCPMC4436437
OpenAlexW1968505161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.